secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVVITY, INC. (RVTY)
CIK:        0000031791
Form:       8-K
Filed at:   2021-07-27T23:59:59+00:00
Accession:  0001193125-21-225700
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PerkinElmer to acquire BioLegend for $5.25B; expects $0.30 adjusted EPS accretion in first full year
--------------------------------------------------------------------------------

- Purchase price ~$5.25B; 59.5% cash and 40.5% stock at $156.3561/share.
- BioLegend estimated 2022 revenues ~$380M with mid-teens-plus growth.
- Expected $0.30 adjusted EPS accretion in 1st full year, >$0.50 in 2nd year.
- Revenue synergies expected $100M annually by 5th year post-close; no significant cost synergies planned.
- Bridge financing of $3.3B committed by Goldman Sachs; no financing condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/31791/000119312521225700/0001193125-21-225700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/31791/000119312521225700/d205775d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-225700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer